ClinicalTrials.gg
CompletedNCT05439616Updated Apr 4, 2025

Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD

A Phase 3 interventional study of Cariprazine and Placebo in Autism Spectrum Disorder, sponsored by AbbVie. Completed at 36 sites in 2 countries. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-04-04.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2024, 2 years 1 month ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Apr 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
161
Allocation
Randomized
Ages
5 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 773 studies in Autism Spectrum Disorder with a site in United States — 165 open to participants now, 204 under way, 9 of them phase 3. Autism Spectrum Disorder · United States.

Enrollment
91st of 658
161 · median 50
Started
2022
with 56 others
Phase 3
25 of 773
6 open now
Registered
555th of 773
by date

Among the 773 studies in Autism Spectrum Disorder with a site in United States, this one is the 91st largest by enrollment of the 658 interventional ones that give a count, is one of 57 that started in 2022, is one of 25 in phase 3, and was the 555th registered.

Autism Spectrum Disorder

1,728 studies on the registry are indexed under Autism Spectrum Disorder; 501 are open to participants now.

Browse Autism Spectrum Disorder studies →

Open to participants now

165 of the 773 studies in Autism Spectrum Disorder with a site in United States are open now. Recruiting first, the newest first:

160 more — sign in →

All 165 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 350 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 295 (84%) stop at 75 or younger; 299 take children under 18; 92 take healthy volunteers.

This study: 5 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 773 studies in Autism Spectrum Disorder with a site in United States, or all of them as a file.
02

Study summary

Autism spectrum disorder (ASD) consists of deficits in social, communication, and cognitive development, repetitive and stereotypic behaviors. Many ASD patients show notably high levels of irritability, including verbal and physical aggression, self injury, and/or property destruction. Autistic infants tend to avoid eye contact and show little interest in others. This study will assess how safe and effective cariprazine is in treating pediatric participants (5 to 17 years of age) with ASD. Adverse events and change in disease activity will be assessed.

Cariprazine is an investigational drug being developed for the treatment of irritability due to ASD. This study is double-blinded means that neither the participants nor the study doctors will know who will be given cariprazine and who will be given placebo (does not contain treatment drug). Study doctors put the participants in 1 of the 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 2 chance that participants will be assigned to placebo. Approximately 152 participants diagnosed with ASD will be enrolled in approximately 40 sites globally.

Participants will receive oral capsules or oral solution of cariprazine or placebo once daily for 8-weeks and will undergo a 4-week safety follow-up period.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.

03

Conditions studied

  • Autism Spectrum Disorder

Keywords

  • Autism Spectrum Disorder
  • Cariprazine
  • VRAYLAR
  • AGN-241780
04

Who can participate

Ages eligible
5 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants at the time of screening must have a , Fifth Edition (DSM-5) diagnosis of ASD, confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia-Present and Lifetime (K-SADS-PL) administered at screening (Visit 1) by a trained clinician.
  • Participants must have an Aberrant Behavior Checklist, 2nd edition - Community Version - Irritability (ABC-I) subscale score ≥ 18 (Visits 1 and 2).
  • Participants must have a Clinical Global Impressions - Severity - Irritability (CGI-S Irritability) score ≥ 4 at screening (Visits 1 and 2).

Exclusion criteria

Exclusion Criteria:

  • Participants with diagnosis of intellectual disability (Intelligence quotient \< 25).
  • No history of major depressive disorder, bipolar disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, or psychotic disorder due to another medical condition, as excluded by administration of Kiddie Schedule for Affective Disorders and Schizophrenia-Present and Lifetime (K-SADS-PL).
  • History of ASD that is associated with Rett Disorder, Fragile-X Syndrome, or Childhood Disintegrative Disorder.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
161 participants (actual)

Study arms

  • Experimental
    Cariprazine

    Participants will receive age-and weight dependent flexible doses of cariprazine once daily for 8-weeks.

    Drug: Cariprazine

  • Placebo comparator
    Placebo

    Participants will receive placebo once daily for 8-weeks.

    Drug: Placebo

Interventions

  • Oral Capsules or Oral Solution

    Also known as: VRAYLAR, AGN-241780

  • DrugPlacebo

    Oral capsules or Oral Solution

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Aberrant Behavior Checklist, 2nd edition - Community Version - Irritability (ABC-I) Subscale Score

    The Aberrant Behavior Checklist (ABC) - Community version is a 58-item, caregiver-rated scale designed to measure inappropriate and maladaptive behavior of people with developmental disabilities (including intellectual disability and ASD). The ABC has 5 subscales (Irritability, Social Withdrawal, Stereotypic Behavior, Hyperactivity and Inappropriate Speech). The caregiver rates the child's behavior from 0=not at all a problem to 3= the problem is severe in degree. The range for Irritability is 0 to 45. Higher scores indicate greater severity.

    Time frame: Baseline (Week 0) to Week 8

Secondary outcomes

  1. Percentage of Participants with responder status of "Very Much Improved" or "Much Improved" on the Clinical Global Impression- Change Irritability (CGI-C Irritability) Scale

    The Clinical Global Impression - Change-Irritability (CGI-C Irritability) is a single-item rating scale that assesses change in the severity of a participant's irritability from the clinician's perspective. The CGI-C Irritability 7-point graded response scale (1 = "Very much improved," 2 = "Much improved," 3 = "Minimally improved," 4 = "No change," 5 = "Minimally worse," 6 = "Much worse," or 7 = "Very much worse").

    Time frame: Week 8

  2. Change from Baseline in Parent-Rated Anxiety Scale for Youth with Autism Spectrum Disorder (PRAS-ASD) Total Score

    PRAS-ASD is a 25-item caregiver-reported measure of anxiety in participants aged 3 to 17 with ASD. All items use a 4-point response scale: 0 = "None (not present);" 1 = "Mild (present sometimes, not a real problem);" 2 = "Moderate (often present and a problem);" 3 = "Severe (very frequent and a major problem)." Total score ranges from 0 to 75, with higher scores indicating greater severity of anxiety.

    Time frame: Baseline (Week 0) to Week 8

  3. Change from Baseline in Caregiver Strain Questionnaire Short Form 7-Item (CGSQ SF-7) total score

    CGSQ SF-7 is a caregiver-reported 7-item measure of self-reported strain that focuses on the impact of caring for a child with emotional and behavioral problems. Responses are scored on a 5-point scale (1 = "Not at all," 2 = "A little;" 3 = "Somewhat;" 4 = "Quite a bit;" and 5 "Very much") with higher scores indicating greater caregiver strain.

    Time frame: Baseline (Week 0) to Week 8

07

Study locations

36 sites
  • Advanced Research Center /ID# 245049
    Anaheim, California 92805, United States
  • Sun Valley Research Center /ID# 243133
    Imperial, California 92251-9401, United States
  • CHOC Children's Hospital /ID# 245577
    Orange, California 92868-4203, United States
  • Pacific Clinical Research Management Group /ID# 243019
    Upland, California 91786, United States
  • D&H Doral Research Center-Doral /ID# 255457
    Doral, Florida 33122, United States
  • Sarkis Clinical Trials /ID# 242868
    Gainesville, Florida 32607, United States
  • Advanced Research Institute of Miami /ID# 243179
    Homestead, Florida 33030-4613, United States
  • Sandhill Research LLC /ID# 245079
    Lake Mary, Florida 32746, United States
  • Axcess Medical Research /ID# 244952
    Loxahatchee Groves, Florida 33470, United States
  • G+C Research Group, LLC /ID# 252016
    Miami, Florida 33126-2018, United States
  • Medical Research Group of Central Florida /ID# 243170
    Orange City, Florida 32763, United States
  • K2 Medical Research - Orlando - South Orlando Avenue /ID# 248694
    Orlando, Florida 32751, United States
  • APG Research, LLC /ID# 243130
    Orlando, Florida 32803, United States
  • Nona Pediatric Center /ID# 245078
    Orlando, Florida 32829-8070, United States
  • Asclepes Research Centers - Spring Hill /ID# 248682
    Spring Hill, Florida 34609-5692, United States
  • D&H Tamarac Research Center /ID# 250436
    Tamarac, Florida 33321-2979, United States
  • Atlanta Center for Medical Research /ID# 243124
    Atlanta, Georgia 30331, United States
  • Atlanta Behavioral Research, LLC /ID# 243082
    Dunwoody, Georgia 30338, United States
  • iResearch Savannah /ID# 254582
    Savannah, Georgia 31405, United States
  • Alivation Research /ID# 242915
    Lincoln, Nebraska 68526-9474, United States
  • Dr. Hosneara, M.D. LLC /ID# 252129
    Jackson Heights, New York 11372-3922, United States
  • Richmond Behavioral Associates An Evolution Research Group Portfolio Company /ID# 259578
    Staten Island, New York 10314-1607, United States
  • New Dawn Psychiatric Services PLLC /ID# 243697
    Kinston, North Carolina 28501-1603, United States
  • Quest Therapeutics of Avon Lake /ID# 252013
    Avon Lake, Ohio 44012, United States
  • Cincinnati Children's Hospital /ID# 243968
    Cincinnati, Ohio 45229, United States
  • CincyScience /ID# 242993
    West Chester, Ohio 45069, United States
  • BioBehavioral Research of Austin /ID# 255460
    Austin, Texas 78759, United States
  • Relaro Medical Trials /ID# 243126
    Dallas, Texas 75243, United States
  • Cedar Health Research /ID# 248683
    Dallas, Texas 75251-2202, United States
  • AIM Trials /ID# 243120
    Plano, Texas 75093, United States
  • Family Psychiatry of The Woodlands /ID# 242867
    The Woodlands, Texas 77381, United States
  • Advanced Research Institute /ID# 243098
    Ogden, Utah 84405, United States
  • Northwest Clinical Research Center /ID# 243083
    Bellevue, Washington 98007, United States
  • Core Clinical Research /ID# 243084
    Everett, Washington 98201, United States
  • Dr. Samuel Sanchez PSC /ID# 245739
    Caguas, 00727, Puerto Rico
  • GCM Medical Group PSC /ID# 245735
    San Juan, 00917-3104, Puerto Rico
08

References and documents

Related links

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Oct 2024, 26 months.

Of 18 phase 3 interventional studies under Autism Spectrum Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 38. This study's 26 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2022
First posted
Jun 30, 2022
StartActual
Jul 7, 2022
Primary completionActual
Oct 4, 2024
CompletionActual
Oct 4, 2024
Results delay requested
Apr 2, 2025
Last update
Apr 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05439616
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jun 30, 2022
Start date
Jul 7, 2022
Primary completion
Oct 4, 2024
Completion
Oct 4, 2024
Last update
Apr 4, 2025

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cariprazine

Start the discussion